| Role |
Name |
Disclosure |
Details |
| Author | Sandip P Vasavada, MD, Co-Head, Section of Female Urology, Joint Appointment, Urological Institute and Department of Gynecology, Co-Director, Center for Pelvic Neuromodulation, Cleveland Clinic Foundation | pfizer allergan ndi medical, LLC novartis | Details | | Coauthor | Raymond Rackley, MD, Professor of Surgery, Cleveland Clinic Lerner College of Medicine at CWRU; Co-Section Head, Section of Voiding Dysfunction and Female Urology, Glickman Urological Institute, Cleveland Clinic Foundation | Pfizer, Novartis, Proctor & Gamble, Allergan Pfizer, Novartis, Proctor & Gamble, Allergan | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Shlomo Raz, MD, Professor, Department of Surgery, Division of Urology, University of California at Los Angeles School of Medicine | Nothing to disclose | Details | | CME Editor | J Stuart Wolf, Jr, MD, FACS, David A Bloom Professor of Urology, Director, Division of Minimally Invasive Urology, Department of Urology, University of Michigan Medical Center | Terumo Corporation Omeros Corporation | Details | | Chief Editor | Stephen W Leslie, MD, FACS, Founder and Medical Director of the Lorain Kidney Stone Research Center, Clinical Assistant Professor, Department of Urology, Medical College of Ohio | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Shlomo Raz, Managing Editor |
The contributor discloses no conflict of interest. |
|